Filing Details

Accession Number:
0001437749-23-015170
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-18 18:53:52
Reporting Period:
2023-05-16
Accepted Time:
2023-05-18 18:53:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1158895 Lemaitre Vascular Inc LMAT Surgical & Medical Instruments & Apparatus (3841) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1365737 W George Lemaitre C/O Lemaitre Vascular, Inc.
63 Second Avenue
Burlington MA 01803
Chairman And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-16 8,610 $35.48 2,357,923 No 4 M Direct
Common Stock Acquisiton 2023-05-16 7,837 $37.29 2,365,760 No 4 M Direct
Common Stock Acquisiton 2023-05-16 7,734 $48.60 2,373,494 No 4 M Direct
Common Stock Disposition 2023-05-17 2,143 $64.05 2,371,351 No 4 S Direct
Common Stock Disposition 2023-05-17 33 $64.82 2,371,318 No 4 S Direct
Common Stock Disposition 2023-05-18 17,660 $63.26 2,353,658 No 4 S Direct
Common Stock Disposition 2023-05-18 250 $64.02 2,353,408 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-05-16 8,610 $0.00 8,610 $35.48
Common Stock Stock Option (Right to Buy) Disposition 2023-05-16 7,837 $0.00 7,837 $37.29
Common Stock Stock Option (Right to Buy) Disposition 2023-05-16 7,734 $0.00 7,734 $48.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,220 2019-12-20 2026-12-20 No 4 M Direct
23,508 2020-12-02 2027-12-02 No 4 M Direct
23,200 2021-12-11 2028-12-11 No 4 M Direct
Footnotes
  1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
  2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $63.77 to $64.47 The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
  3. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $62.94 to $63.92 The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
  4. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $63.94 to $64.27 The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
  5. This option is exercisable and vests over a five-year period at a rate of 20% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining four years.
  6. This option is exercisable and vests over a five-year period at a rate of 20% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining four years with the final vesting occurring on the eleventh month after the fourth anniversary.
  7. This option is exercisable and vests over a four-year period at a rate of 25% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining three years.